Hospital
Atrium Medical Center
Atrium Medical Center was paid $27.62M by Medicaid between Jan 2018 and Dec 2024, across 265 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoATRIUM MEDICAL CENTER
FRANKLIN, OH 45005
FRANKLIN, OH 45005
33aNPI1700950060assigned 11/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$27.62M
24GClaims626,124
24DCodes billed265
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#42 of 101
Median peer was paid$22.32M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 80,931 | $3.11M | |
| 2019 | 61,882 | $2.48M | |
| 2020 | 46,000 | $2.93M | |
| 2021 | 30,177 | $1.96M | |
| 2022 | 39,626 | $2.36M | |
| 2023 | 221,051 | $8.94M | |
| 2024incomplete | 146,457 | $5.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 30,366 | 26,788 | $3.87M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 12,710 | 9,865 | $3.65M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 32,525 | 26,651 | $3.47M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 28,585 | 26,072 | $3.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 17,722 | 15,464 | $2.47M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 4,644 | 3,712 | $1.12M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 9,241 | 2,508 | $716K |
| 11043 | 2.4% | 2,238 | 1,225 | $671K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 3,011 | 2,282 | $658K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 4,724 | 3,869 | $567K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.7% | 678 | 570 | $470K |
| G0378 | Hospital observation service, per hour | 1.6% | 6,742 | 2,461 | $440K |
253 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.5% | 3,692 | $406K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 3,834 | $375K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 3,508 | $355K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 1,211 | $287K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 696 | $286K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.0% | 1,425 | $278K |
| 59025 | Fetal non-stress test | <1% | 1,758 | $272K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,052 | $253K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 5,520 | $226K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,197 | $221K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29,153 | $204K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,091 | $190K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,204 | $178K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 665 | $171K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 5,904 | $158K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 574 | $117K |
| 70496 | <1% | 475 | $113K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,431 | $97K |
| 80053 | Comprehensive metabolic panel | <1% | 12,952 | $87K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 968 | $84K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 402 | $83K |
| 95811 | <1% | 116 | $81K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 714 | $76K |
| 76830 | Ultrasound, transvaginal | <1% | 742 | $72K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,151 | $69K |
| 76642 | <1% | 546 | $65K | |
| 93017 | <1% | 776 | $63K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,311 | $61K |
| 93970 | <1% | 468 | $60K | |
| 84484 | <1% | 17,112 | $56K | |
| 93971 | <1% | 718 | $48K | |
| 97161 | <1% | 1,142 | $48K | |
| 72131 | <1% | 722 | $41K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 213 | $40K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 274 | $39K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,801 | $39K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,756 | $38K |
| 71250 | <1% | 452 | $35K | |
| 71045 | Radiologic examination, chest; single view | <1% | 18,522 | $27K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 191 | $25K |
| 97116 | <1% | 1,251 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,177 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,281 | $24K |
| 80320 | <1% | 2,329 | $23K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 98 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 42,847 | $21K |
| 87400 | <1% | 1,054 | $21K | |
| 97162 | <1% | 711 | $21K | |
| 93458 | <1% | 16 | $20K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 54 | $20K |
| 95819 | <1% | 128 | $18K | |
| 86850 | <1% | 1,134 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,208 | $18K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 493 | $15K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,299 | $15K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 240 | $15K |
| 70486 | <1% | 540 | $14K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 536 | $14K |
| 90715 | <1% | 940 | $14K | |
| 74018 | <1% | 414 | $13K | |
| 76536 | <1% | 101 | $13K | |
| 88341 | <1% | 477 | $13K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,542 | $12K |
| 86900 | <1% | 1,246 | $12K | |
| 97597 | <1% | 109 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 988 | $11K |
| 72100 | <1% | 339 | $10K | |
| 0002A | <1% | 312 | $10K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 15 | $10K |
| 0001A | <1% | 338 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,763 | $8K |
| 97166 | <1% | 280 | $8K | |
| 73560 | <1% | 613 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 283 | $8K |
| J3490 | Unclassified drugs | <1% | 4,387 | $8K |
| 73030 | <1% | 814 | $8K | |
| 85027 | <1% | 2,908 | $8K | |
| 72128 | <1% | 337 | $8K | |
| 81001 | <1% | 19,874 | $7K | |
| 87070 | <1% | 1,566 | $7K | |
| 74178 | <1% | 64 | $7K | |
| 12001 | <1% | 54 | $7K | |
| 96376 | <1% | 3,028 | $6K | |
| 77066 | Tomosynthesis, mammo | <1% | 350 | $6K |
| 70491 | <1% | 19 | $6K | |
| 73610 | <1% | 657 | $6K | |
| 73630 | <1% | 894 | $5K | |
| 96367 | <1% | 164 | $5K | |
| 73130 | <1% | 759 | $5K | |
| 70498 | <1% | 464 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,915 | $5K |
| 81025 | <1% | 10,811 | $4K | |
| 80076 | <1% | 445 | $4K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 269 | $4K |
| 85610 | <1% | 3,706 | $4K | |
| 97113 | <1% | 97 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 16 | $3K |
| 73562 | <1% | 328 | $3K | |
| 95886 | <1% | 14 | $3K | |
| 73502 | <1% | 300 | $3K | |
| 82565 | <1% | 415 | $3K | |
| 76775 | <1% | 40 | $3K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 40 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,012 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,430 | $3K |
| 82248 | <1% | 7,060 | $3K | |
| 80061 | Lipid panel | <1% | 505 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 659 | $3K |
| 80055 | <1% | 118 | $3K | |
| 83735 | <1% | 2,359 | $3K | |
| 87040 | <1% | 1,723 | $3K | |
| 12011 | <1% | 14 | $2K | |
| 71271 | <1% | 14 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 733 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,460 | $2K |
| H1002 | Prenatal care, at risk enhanced service; care coordination | <1% | 546 | $2K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 122 | $2K |
| 73110 | <1% | 311 | $2K | |
| 88142 | <1% | 128 | $2K | |
| 86901 | <1% | 1,246 | $2K | |
| 85730 | <1% | 2,761 | $2K | |
| 84439 | <1% | 427 | $2K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 516 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,810 | $1K |
| 83690 | <1% | 8,008 | $1K | |
| 97163 | <1% | 81 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,952 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 985 | $1K |
| 73590 | <1% | 338 | $1K | |
| 83880 | <1% | 1,277 | $1K | |
| 83605 | <1% | 1,795 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 987 | $1K |
| 90686 | <1% | 33 | $1K | |
| 72141 | <1% | 17 | $1K | |
| 82550 | <1% | 711 | $991.89 | |
| 82950 | <1% | 133 | $990.74 | |
| 76937 | <1% | 16 | $978.57 | |
| 85379 | <1% | 1,390 | $895.48 | |
| 87430 | <1% | 1,483 | $866.14 | |
| 72040 | <1% | 22 | $861.95 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $814.34 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,914 | $813.17 |
| 97167 | <1% | 87 | $805.86 | |
| 82803 | <1% | 1,201 | $801.76 | |
| 81000 | <1% | 2,759 | $782.67 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 755 | $748.51 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 30 | $739.91 |
| 87088 | <1% | 2,378 | $724.05 | |
| 84100 | <1% | 448 | $719.14 | |
| 84702 | <1% | 698 | $715.66 | |
| 81003 | <1% | 2,077 | $684.95 | |
| 87147 | <1% | 524 | $681.35 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,865 | $651.79 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,731 | $640.73 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 48 | $640.24 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 177 | $565.42 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,663 | $542.68 |
| 85014 | <1% | 379 | $524.34 | |
| 72110 | <1% | 14 | $493.39 | |
| 87077 | <1% | 1,218 | $469.64 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 180 | $451.72 |
| 72170 | <1% | 440 | $404.11 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 441 | $389.82 |
| J1815 | Injection, insulin, per 5 units | <1% | 586 | $358.09 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 51 | $298.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,431 | $296.95 |
| 85018 | <1% | 384 | $289.18 | |
| 87186 | <1% | 1,186 | $282.10 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 318 | $256.09 |
| 73552 | <1% | 84 | $255.31 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 246 | $247.96 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,257 | $236.39 |
| 80069 | <1% | 21 | $217.84 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 825 | $181.07 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 158 | $174.11 |
| 80143 | <1% | 380 | $172.05 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,961 | $167.27 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 35 | $150.96 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,492 | $147.52 |
| 82010 | <1% | 204 | $145.70 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 230 | $137.14 |
| 84703 | <1% | 137 | $136.92 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 984 | $128.68 |
| 90656 | <1% | 12 | $123.67 | |
| 88342 | <1% | 621 | $117.86 | |
| 82140 | <1% | 117 | $112.94 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 163 | $107.96 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 185 | $107.45 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 121 | $102.14 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 834 | $99.57 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $76.59 |
| 82330 | <1% | 49 | $72.71 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 375 | $71.79 |
| 87210 | <1% | 121 | $71.02 | |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | <1% | 117 | $70.17 |
| 73080 | <1% | 13 | $67.89 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,015 | $59.75 |
| 80179 | <1% | 335 | $57.33 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 794 | $55.31 |
| 86140 | <1% | 30 | $52.80 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,399 | $50.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,169 | $45.00 |
| 87075 | <1% | 53 | $43.73 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,286 | $42.49 |
| 73090 | <1% | 150 | $37.77 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 324 | $32.33 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,300 | $31.50 |
| 84132 | <1% | 39 | $30.52 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 92 | $23.95 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 122 | $22.79 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 105 | $16.52 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 40 | $15.81 |
| 85652 | <1% | 69 | $13.83 | |
| 87205 | <1% | 24 | $12.04 | |
| 87176 | <1% | 16 | $9.43 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 118 | $9.30 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 60 | $7.60 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 69 | $7.52 |
| 91300 | <1% | 590 | $5.13 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 217 | $4.79 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 212 | $2.54 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 154 | $2.36 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 768 | $2.20 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 63 | $2.01 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 24 | $1.95 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 651 | $0.48 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 5,604 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 175 | $0.00 |
| H1000 | Prenatal care, at-risk assessment | 0% | 109 | $0.00 |
| 94060 | 0% | 16 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 234 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 893 | $0.00 |
| 00840 | 0% | 32 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 72 | $0.00 |
| 94726 | 0% | 16 | $0.00 | |
| 94729 | 0% | 16 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 14 | $0.00 |
| 73070 | 0% | 13 | $0.00 | |
| 99078 | 0% | 29 | $0.00 | |
| 00731 | 0% | 14 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 14 | $0.00 |
| 88304 | 0% | 215 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 557 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 30 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 789 | $0.00 |
| A9270 | Non-covered item or service | 0% | 124 | $0.00 |
| 94761 | 0% | 15 | $0.00 | |
| 82607 | 0% | 17 | $0.00 | |
| C1769 | Guide wire | 0% | 280 | $0.00 |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | 0% | 45 | $0.00 |
| 82746 | 0% | 15 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 39 | $0.00 |
| 81015 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHELTON, SCOTT (VP FINANCE)